

TYPES OF SUPPORT

You are here: Types of support ▾ New and underused vaccines support ▾ Human papillomavirus vaccine



Human papillomavirus vaccine support

Gavi's response

The issue




Record low price agreed for HPV vaccines

A record low price for HPV vaccines has opened the door for poor countries to vaccinate millions of girls against a devastating women's cancer.

Thanks to the Vaccine Alliance, the poorest countries now have access to a sustainable supply of HPV vaccines for as low as US\$ 4.50 per dose. The same vaccines can cost more than \$100 in developed countries and the previous lowest public sector price was \$13 per dose.

For HPV demonstration programmes, Gavi will cover the full cost of HPV vaccines. However, countries introducing HPV vaccine nationally are required to meet the standard co-financing commitment.

HPV vaccines are available in the routine immunisation programmes of mostly high-income countries. And yet of the 266,000 women in the world who die of cervical cancer every year, more than 85% are in low-income countries where access to cancer



- NEW AND UNDERUSED VACCINES SUPPORT
- Human papillomavirus vaccine
- Inactivated polio vaccine
- Injection safety support
- Japanese encephalitis vaccine
- Measles vaccine
- Meningitis A vaccine
- Pentavalent vaccine
- Pneumococcal vaccine
- Measles-Rubella vaccine
- Rotavirus vaccine
- Yellow fever vaccine

screening and treatment services is often lacking.

The high cost of the vaccine and challenges of immunising girls aged 9 to 13 years have been barriers to introduction in poorer countries. Gavi is working to bridge the equity gap by providing the vaccine at affordable and sustainable prices, and to support countries with demonstration projects in order to build capacity and infrastructure to deliver the vaccines.

Since Gavi began providing support for HPV vaccines in 2013, over 20 countries have been approved to introduce the vaccines - the large majority will be HPV demonstration projects. This will allow them to test the best ways to deliver HPV vaccines to girls. These demonstration projects will pave the way for countries to build the capacity and infrastructure needed to vaccinate girls nationwide. Rwanda will introduce HPV vaccine nationally. By 2020, it is estimated that over 30 million girls in more than 40 countries will be vaccinated against HPV.

THE VACCINE

Safe and effective human papillomavirus (HPV) vaccines protect against HPV types 16 and 18 which cause about 70% of cervical cancer cases.

Cervical cancer is a leading cause of cancer deaths among women in Gavi-eligible countries. Gavi's commitment to protecting women against cervical cancer supports the UN Secretary-General's Global Strategy on Women's and Children's Health to address key global health priorities by increasing access to life-saving vaccines.

TWO APPLICATION PATHWAYS

Countries that have demonstrated the ability to deliver HPV vaccine to adolescent girls, can apply for national introduction support. Demonstrated ability is defined as prior experience in delivering multi-dose vaccines to at least 50% of a target population of 9-13 year old girls in an average-sized district; please see [Gavi new and underused vaccines support \(in English and French\)](#) for more details. Countries lacking experience can apply for support to conduct smaller-scale demonstration projects in order to gain the experience necessary to apply for national roll-out.

WORKING WITH PARTNERS

FEEDBACK



Professor Ian Frazer
creator of the HPV vaccine

“Today's announcement by GAVI of country approvals for HPV demonstration projects is another big step forward to ensuring that girls living in developing countries enjoy the same access to HPV vaccines as girls elsewhere in the world.”

RELATED EVENTS

[2011 World Cancer Leaders' Summit](#)

IMMUNISATION IN THE NEWS



02 October 2013

[Laos becomes first South East Asian nation to introduce pneumococcal vaccine](#)

Xinhua

RESOURCES



[HPV and related cancers in Gavi Countries. WHO/ICO HPV Information Centre Report, 2012](#)

[Gavi factsheet on human papillomavirus](#)

[PMNCH Knowledge Summary 15: Non-communicable diseases](#)

[Working Towards Affordable Pricing for HPV Vaccines for Developing Countries: The Role of Gavi](#)

[Women Deliver - Delivering cervical cancer prevention in the developing world](#)

US\$ 80-100 billion

Investing in Gavi's 2016-2020 strategy has the potential to deliver US\$ 80-100 billion in costs averted related to illness, such as productivity loss due to death/disability, treatment costs, caretaker productivity loss and transport costs.

Gavi is partnering with cancer, reproductive health and women's organisations to help countries deliver HPV vaccines cost-effectively, integrated with other important interventions for girls such as adolescent reproductive health, HIV prevention, nutrition, family planning and safe motherhood.

Initial experience in offering HPV vaccination in Africa, Asia and Latin America has been encouraging. Lessons learnt documents are available through the [Reproductive Health Outlook Cervical Cancer library](#).

WHO, the [Alliance for Cervical Cancer Prevention](#), the [Cervical Cancer Action coalition](#) and the [UNFPA](#) have called for comprehensive cervical cancer prevention plans that include both vaccination of young girls and screening and treatment of women.

[HPV vaccine demonstration programmes map](#)

[HPV Supply and Procurement Roadmap](#)

[More facts...](#)

RELATED DOCUMENT



[World Cancer Report 2014 press release](#)

PARTNERS

Many organisations are actively involved with clinical and operational research, policy analysis, and advocacy related to HPV vaccine. Collaborating partners and their main roles include:

[World Health Organization \(WHO\)](#) offer technical information, standards and guidelines;

[United Nations Population Fund \(UNFPA\)](#) brings expertise in reproductive health;

[International Agency for Research on Cancer \(IARC\)](#) carry out epidemiological studies assessing HPV type-specific prevalence among various populations;

[The Cervical Cancer Action coalition](#) for advocacy and education;

[Alliance for Cervical Cancer Prevention](#) provides news, resources, advocacy and information;

[PATH](#) supports operational research in India, Peru, Uganda and Vietnam to inform decisions about how to introduce HPV vaccines;

Vaccine manufacturers and academia conduct clinical research;

Gavi offers financial support for the introduction of vaccines into the routine immunisation of eligible countries.

More on this topic

From the Gavi site



[More than 30 million girls to be immunised with HPV vaccines by 2020 with GAVI support](#)



[Making vaccines more affordable](#)

From other sites

- [WHO/ICO Information Centre on Human Papilloma Virus and Cervical Cancer](#)
- [Alliance for Cervical Cancer Prevention](#)
- [American Cancer Society](#)
- [International Agency for Research on Cancer \(IARC\)](#)
- [The Cervical Cancer Action coalition](#)
- [PATH](#)
- [United Nations Population Fund \(UNFPA\)](#)
- [WHO | Cancer of the cervix](#)
- ['One in six cancers worldwide are caused by infection'](#)

[Home](#)

First time visitors

[About Gavi](#)

Gavi's mission

[Types of support](#)

Apply for support

[Country hub](#)

Select a country

[Funding & finance](#)

How Gavi is funded

[Results & evidence](#)

Goal-level indicators

[Library & news](#)

News

Board members	Gavi's strategy	New and underused vaccines support	Key figures: donor contributions & pledges	Countries approved for support	Audio-visual
Civil society	Value of vaccination		Donor profiles	Disbursements by country	Board & committee minutes
Developing countries	Gavi's partnership model	Immunisation services support	Financial reports	Gavi's evaluation studies	Gavi documents
Donors	Gavi's business model	Health system strengthening	Gavi Matching Fund	Gavi Progress reports	Publications
Journalists	Global health and development	Civil society organisation	International Finance Facility for Immunisation		Events
	Governing Gavi		Pneumococcal AMC		



[Contact](#)
[Careers](#)
[Follow Gavi](#)
[Terms of use](#)
[Immunize Every Child](#)
[IFFIm](#)

Glossary: [A-E](#) [F-J](#) [K-O](#) [P-T](#) [U-Z](#)

© Gavi 2014